Vanta Bioscience Ltd

Vanta Bioscience Ltd

Vanta Bioscience Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 to consider and approve the Standalone and Consolidated unaudited Financial Results of the Company for the half year ended September 30, 2026.

Vanta Bioscience Ltd

Vanta Bioscience Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 to consider and approve the Standalone and Consolidated unaudited Financial Results of the Company for the half year ended September 30, 2026.

Vanta Bioscience Ltd

Vanta Bioscience Ltd has submitted the proceedings, voting results, and scrutinizer's report for its 10th Annual General Meeting, which was held on September 30, 2026. The meeting was attended by 10 members physically, and the resolutions were passed with the requisite majority.

Vanta Bioscience Ltd

Vanta Bioscience Ltd has submitted the proceedings, voting results, and scrutinizer's report for its 10th Annual General Meeting (AGM), which was held on September 30, 2026. The meeting was attended by 10 members physically, and the resolutions were passed with the requisite majority.

Vanta Bioscience Ltd

Vanta Bioscience Ltd has announced the closure of its trading window for all designated persons, their immediate relatives, and other concerned persons, effective from October 01, 2026, until 48 hours after the declaration of unaudited financial results for the half year ended September 30, 2026.

Vanta Bioscience Ltd

Vanta Bioscience Ltd has submitted its 10th Annual Report for FY 2025-26, including audited standalone and consolidated financial statements, and has announced the re-appointment of its Managing Director, Dopesh Raja Mulakala, for another term of 3 years.